secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193805-23-000700
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic Q1 net loss $25.3M; positive phase 1b IMU-856 celiac data; cash $97.1M
------------------------------------------------------------------------------

- Q1 net loss $25.3M ($0.58/sh) vs $20.8M ($0.74/sh); R&D expenses $23.0M up from $17.4M YoY.
- Cash, equivalents and investments $97.1M as of Mar 31, 2023; expected to fund operations into Q4 2024.
- Positive phase 1b IMU-856 celiac data: proof-of-concept with improvements in histology, symptoms, biomarkers, nutrient absorption.
- Interim results from phase 2 CALLIPER trial of vidofludimus calcium in progressive MS expected H2 2023.
- Richard Rudick, M.D. added to board Apr 26, 2023; Vincent Ossipow, Ph.D. to step down June 28, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523000700/0001193805-23-000700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523000700/e618615_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-000700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer